sr 95531 has been researched along with phosphorylethanolamine in 1 studies
| Studies (sr 95531) | Trials (sr 95531) | Recent Studies (post-2010) (sr 95531) | Studies (phosphorylethanolamine) | Trials (phosphorylethanolamine) | Recent Studies (post-2010) (phosphorylethanolamine) |
|---|---|---|---|---|---|
| 610 | 0 | 209 | 601 | 7 | 230 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Debnath, ML; Klunk, WE; McClure, RJ; Pettegrew, JW | 1 |
1 other study(ies) available for sr 95531 and phosphorylethanolamine
| Article | Year |
|---|---|
Inactivity of phosphoethanolamine, an endogenous GABA analog decreased in Alzheimer's disease, at GABA binding sites.
Topics: Alzheimer Disease; Animals; Ethanolamines; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Male; Muscimol; Pyridazines; Rats; Rats, Inbred F344; Receptors, GABA; Receptors, GABA-A; Receptors, GABA-B; Tritium | 1995 |